Mesenchymal stromal cells in renal transplantation: Opportunities and challenges

Nature Reviews Nephrology

Volumn 12, Issue 4, 2016, Pages 241-253

  Casiraghi, Federica ^a   Perico, Norberto ^a   Cortinovis, Monica ^a   Remuzzi, Giuseppe ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOIMMUNITY; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; B LYMPHOCYTE; CARDIAC GRAFT REJECTION; DENDRITIC CELL; HEART TRANSPLANTATION; HUMAN; IMMUNE RESPONSE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); T LYMPHOCYTE; ALLOTRANSPLANTATION; ANIMAL; ANTIGEN PRESENTING CELL; GRAFT REJECTION; IMMUNOLOGY; KIDNEY FAILURE, CHRONIC; PROCEDURES; REGULATORY T LYMPHOCYTE; TRANSPLANTATION TOLERANCE;

IMMUNOSUPPRESSIVE AGENT;

ANIMALS; ANTIGEN-PRESENTING CELLS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION TOLERANCE; TRANSPLANTATION, HOMOLOGOUS;

EID: 84957837941     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2016.7     Document Type: Article

References (121)

1. Kotton C. N., & Fishman J. A. Viral infection in the renal transplant recipient. J. Am. Soc. Nephrol. 16, 1758-1774 (2005
2. Rama I., & Grinyo J. M. Malignancy after renal transplantation: the role of immunosuppression. Nat. Rev. Nephrol. 6, 511-519 (2010
3. Stoumpos S., Jardine A. G., & Mark P. B. Cardiovascular morbidity and mortality after kidney transplantation. Transpl. Int. 28, 10-21 (2015
4. Tufton N., et al. New-onset diabetes after renal transplantation. Diabet. Med. 31, 1284-1292 (2014
5. Casey M. J., & Meier-Kriesche H. U. Calcineurin inhibitors in kidney transplantation: friend or foe? Curr. Opin. Nephrol. Hypertens. 20, 610-615 (2011
6. Lodhi S. A., Lamb K. E., & Meier-Kriesche H. U. Solid organ allograft survival improvement in the United States: the long-term does not mirror the dramatic short-term success. Am. J. Transplant. 11, 1226-1235 (2011
7. Salama A. D., Remuzzi G., Harmon W. E., & Sayegh M. H. Challenges to achieving clinical transplantation tolerance. J. Clin. Invest. 108, 943-948 (2001
8. Kawai T., et al. Long-term results in recipients of combined HLA-mismatched kidney and bone marrow transplantation without maintenance immunosuppression. Am. J. Transplant. 14, 1599-1611 (2014
9. Leventhal J., et al. Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation. Sci. Transl. Med. 4, 124ra28 (2012
10. Scandling J. D., et al. Tolerance and chimerism after renal and hematopoietic-cell transplantation. N. Engl. J. Med. 358, 362-368 (2008
11. Wood K. J., Bushell A., & Hester J. Regulatory immune cells in transplantation. Nat. Rev. Immunol. 12, 417-430 (2012
12. Friedenstein A. J., Chailakhjan R. K., & Lalykina K. S. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet. 3, 393-403 (1970
13. Friedenstein A. J., Chailakhyan R. K., Latsinik N. V., Panasyuk A. F., & Keiliss-Borok I. V. Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. Transplantation 17, 331-340 (1974
14. Owen M., & Friedenstein A. J. Stromal stem cells: marrow-derived osteogenic precursors. Ciba Found. Symp. 136, 42-60 (1988
15. Bianco P., et al. The meaning, the sense and the significance: translating the science of mesenchymal stem cells into medicine. Nat. Med. 19, 35-42 (2013
16. Sacchetti B., et al. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell 131, 324-336 (2007
17. Mendez-Ferrer S., et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 466, 829-834 (2010
18. Bianco P., Robey P. G., & Simmons P. J. Mesenchymal stem cells: revisiting history, concepts, and assays. Cell Stem Cell 2, 313-319 (2008
19. Dominici M., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8, 315-317 (2006
20. Crisan M., et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 3, 301-313 (2008
21. Bautch V. L. Stem cells and the vasculature. Nat. Med. 17, 1437-1443 (2011
22. da Silva Meirelles L., Chagastelles P. C., & Nardi N. B. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J. Cell Sci. 119, 2204-2213 (2006
23. Lechler R. I., Lombardi G., Batchelor J. R., Reinsmoen N., & Bach F. H. The molecular basis of alloreactivity. Immunol. Today 11, 83-88 (1990
24. Zhuang Q., & Lakkis F. G. Dendritic cells and innate immunity in kidney transplantation. Kidney Int. 87, 712-718 (2015
25. Matzinger P., & Bevan M. J. Hypothesis: why do so many lymphocytes respond to major histocompatibility antigens? Cell. Immunol. 29, 1-5 (1977
26. Suchin E. J., et al. Quantifying the frequency of alloreactive T cells in vivo: new answers to an old question. J. Immunol. 166, 973-981 (2001
27. Wood K. J., & Goto R. Mechanisms of rejection: current perspectives. Transplantation 93, 1-10 (2012
28. Liu Z., Fan H., & Jiang S. CD4+ T cell subsets in transplantation. Immunol. Rev. 252, 183-191 (2013
29. Rosenberg A. S., Mizuochi T., Sharrow S. O., & Singer A. Phenotype, specificity, and function of T cell subsets and T cell interactions involved in skin allograft rejection. J. Exp. Med. 165, 1296-1315 (1987
30. Jiang S., Herrera O., & Lechler R. I. New spectrum of allorecognition pathways: implications for graft rejection and transplantation tolerance. Curr. Opin. Immunol. 16, 550-557 (2004
31. Lee C. Y., et al. The involvement of FcR mechanisms in antibody-mediated rejection. Transplantation 84, 1324-1334 (2007
32. Williams M. A., & Bevan M. J. Effector and memory CTL differentiation. Annu. Rev. Immunol. 25, 171-192 (2007
33. Valujskikh A., & Lakkis F. G. In remembrance of things past: memory T cells and transplant rejection. Immunol. Rev. 196, 65-74 (2003
34. Noris M., et al. Regulatory T cells and T cell depletion: role of immunosuppressive drugs. J. Am. Soc. Nephrol. 18, 1007-1018 (2007
35. Pearl J. P., et al. Immunocompetent T cells with a memory-like phenotype are the dominant cell type following antibody-mediated T cell depletion. Am. J. Transplant. 5, 465-474 (2005
36. Williams K. M., Hakim F. T., & Gress R. E. T cell immune reconstitution following lymphodepletion. Semin. Immunol. 19, 318-330 (2007
37. Page A. J., Ford M. L., & Kirk A. D. Memory T cell-specific therapeutics in organ transplantation. Curr. Opin. Organ Transplant. 14, 643-649 (2009
38. Rudensky A. Y. Regulatory T cells and Foxp3. Immunol. Rev. 241, 260-268 (2011
39. Waldmann H., Hilbrands R., Howie D., & Cobbold S. Harnessing FOXP3+ regulatory T cells for transplantation tolerance. J. Clin. Invest. 124, 1439-1445 (2014
40. English K., Barry F. P., & Mahon B. P. Murine mesenchymal stem cells suppress dendritic cell migration, maturation and antigen presentation. Immunol. Lett. 115, 50-58 (2008
41. Chiesa S., et al. Mesenchymal stem cells impair in vivo T cell priming by dendritic cells. Proc. Natl Acad. Sci. USA 108, 17384-17389 (2011
42. Zhang W., et al. Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem Cells Dev. 13, 263-271 (2004
43. Jiang X. X., et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 105, 4120-4126 (2005
44. Nauta A. J., Kruisselbrink A. B., Lurvink E., Willemze R., & Fibbe W. E. Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells. J. Immunol. 177, 2080-2087 (2006
45. Djouad F., et al. Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6 dependent mechanism. Stem Cells 25, 2025-2032 (2007
46. Li Y. P., et al. Human mesenchymal stem cells license adult CD34+ hemopoietic progenitor cells to differentiate into regulatory dendritic cells through activation of the Notch pathway. J. Immunol. 180, 1598-1608 (2008
47. Spaggiari G. M., Abdelrazik H., Becchetti F., & Moretta L. MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Blood 113, 6576-6583 (2009
48. Beyth S., et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T cell unresponsiveness. Blood 105, 2214-2219 (2005
49. Bartholomew A., et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol. 30, 42-48 (2002
50. Glennie S., Soeiro I., Dyson P. J., Lam E. W., & Dazzi F. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 105, 2821-2827 (2005
51. Krampera M., et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 101, 3722-3729 (2003
52. Tse W. T., Pendleton J. D., Beyer W. M., Egalka M. C., & Guinan E. C. Suppression of allogeneic T cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 75, 389-397 (2003
53. Karlsson H., et al. Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T cell responses. Blood 112, 532-541 (2008
54. Reading J. L., et al. Clinical-grade multipotent adult progenitor cells durably control pathogenic T cell responses in human models of transplantation and autoimmunity. J. Immunol. 190, 4542-4552 (2013
55. Rasmusson I., Ringden O., Sundberg B., & Le Blanc K. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 76, 1208-1213 (2003
56. Plumas J., et al. Mesenchymal stem cells induce apoptosis of activated T cells. Leukemia 19, 1597-1604 (2005
57. Meisel R., et al. Human bone marrow stromal cells inhibit allogeneic T cell responses by indoleamine 2,3 dioxygenase-mediated tryptophan degradation. Blood 103, 4619-4621 (2004
58. Aggarwal S., & Pittenger M. F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105, 1815-1822 (2005
59. Di Nicola M., et al. Human bone marrow stromal cells suppress T lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99, 3838-3843 (2002
60. Gieseke F., et al. Human multipotent mesenchymal stromal cells use galectin 1 to inhibit immune effector cells. Blood 116, 3770-3779 (2010
61. Sioud M., Mobergslien A., Boudabous A., & Floisand Y. Evidence for the involvement of galectin 3 in mesenchymal stem cell suppression of allogeneic T cell proliferation. Scand. J. Immunol. 71, 267-274 (2010
62. Nasef A., et al. Immunosuppressive effects of mesenchymal stem cells: involvement of HLA G. Transplantation 84, 231-237 (2007
63. Sato K., et al. Nitric oxide plays a critical role in suppression of T cell proliferation by mesenchymal stem cells. Blood 109, 228-234 (2007
64. Ren G., et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2, 141-150 (2008
65. Ren G., et al. Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells 27, 1954-1962 (2009
66. Luz-Crawford P., et al. Mesenchymal stem cells generate a CD4+CD25+Foxp3+ regulatory T cell population during the differentiation process of Th1 and Th17 cells. Stem Cell Res. Ther. 4, 65 (2013
67. English K., et al. Cell contact, prostaglandin E2 and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25Highforkhead box P3+ regulatory T cells. Clin. Exp. Immunol. 156, 149-160 (2009
68. Selmani Z., et al. Human leukocyte antigen G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells 26, 212-222 (2008
69. Melief S. M., et al. Multipotent stromal cells induce human regulatory T cells through a novel pathway involving skewing of monocytes toward anti-inflammatory macrophages. Stem Cells 31, 1980-1991 (2013
70. Akiyama K., et al. Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand-/FAS-mediated T cell apoptosis. Cell Stem Cell 10, 544-555 (2012
71. Tabera S., et al. The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B lymphocytes. Haematologica 93, 1301-1309 (2008
72. Rosado M. M., et al. Inhibition of B cell proliferation and antibody production by mesenchymal stromal cells is mediated by T cells. Stem Cells Dev. 24, 93-103 (2015
73. Asari S., et al. Mesenchymal stem cells suppress B cell terminal differentiation. Exp. Hematol. 37, 604-615 (2009
74. Franquesa M., et al. Human adipose tissue-derived mesenchymal stem cells abrogate plasmablast formation and induce regulatory B cells independently of T helper cells. Stem Cells 33, 880-891 (2015
75. Zhou H. P., et al. Administration of donor-derived mesenchymal stem cells can prolong the survival of rat cardiac allograft. Transplant. Proc. 38, 3046-3051 (2006
76. Inoue S., et al. Immunomodulatory effects of mesenchymal stem cells in a rat organ transplant model. Transplantation 81, 1589-1595 (2006
77. Chabannes D., et al. A role for heme oxygenase 1 in the immunosuppressive effect of adult rat and human mesenchymal stem cells. Blood 110, 3691-3694 (2007
78. Popp F. C., et al. Mesenchymal stem cells can induce long-term acceptance of solid organ allografts in synergy with low-dose mycophenolate. Transpl. Immunol. 20, 55-60 (2008
79. Roobrouck V. D., et al. Differentiation potential of human postnatal mesenchymal stem cells, mesoangioblasts, and multipotent adult progenitor cells reflected in their transcriptome and partially influenced by the culture conditions. Stem Cells 29, 871-882 (2011
80. Jacobs S. A., Roobrouck V. D., Verfaillie C. M., & Van Gool S. W. Immunological characteristics of human mesenchymal stem cells and multipotent adult progenitor cells. Immunol. Cell Biol. 91, 32-39 (2013
81. Eggenhofer E., et al. Heart grafts tolerized through third-party multipotent adult progenitor cells can be retransplanted to secondary hosts with no immunosuppression. Stem Cells Transl. Med. 2, 595-606 (2013
82. Obermajer N., et al. Conversion of Th17 into IL 17Aneg regulatory T cells: a novel mechanism in prolonged allograft survival promoted by mesenchymal stem cell-supported minimized immunosuppressive therapy. J. Immunol. 193, 4988-4999 (2014
83. Ge W., et al. Infusion of mesenchymal stem cells and rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance. Am. J. Transplant. 9, 1760-1772 (2009
84. Casiraghi F., et al. Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J. Immunol. 181, 3933-3946 (2008
85. Solari M. G., et al. Marginal mass islet transplantation with autologous mesenchymal stem cells promotes long-term islet allograft survival and sustained normoglycemia. J. Autoimmun. 32, 116-124 (2009
86. Kim Y. H., et al. Interleukin (IL)-10 induced by CD11b+ cells and IL 10 activated regulatory T cells play a role in immune modulation of mesenchymal stem cells in rat islet allografts. Mol. Med. 17, 697-708 (2011
87. Wang Y., Zhang A., Ye Z., Xie H., & Zheng S. Bone marrow-derived mesenchymal stem cells inhibit acute rejection of rat liver allografts in association with regulatory T cell expansion. Transplant. Proc. 41, 4352-4356 (2009
88. Jiang X., et al. CD4+CD25+ regulatory T cells are not required for mesenchymal stem cell function in fully MHC-mismatched mouse cardiac transplantation. Cell Tissue Res. 358, 503-514 (2014
89. Ge W., et al. Regulatory T cell generation and kidney allograft tolerance induced by mesenchymal stem cells associated with indoleamine 2,3 dioxygenase expression. Transplantation 90, 1312-1320 (2010
90. He Y., et al. Indoleamine 2, 3 dioxgenase transfected mesenchymal stem cells induce kidney allograft tolerance by increasing the production and function of regulatory T cells. Transplantation 99, 1829-1838 (2015
91. Franquesa M., et al. Mesenchymal stem cell therapy prevents interstitial fibrosis and tubular atrophy in a rat kidney allograft model. Stem Cells Dev. 21, 3125-3135 (2012
92. Hara Y., et al. In vivo effect of bone marrow-derived mesenchymal stem cells in a rat kidney transplantation model with prolonged cold ischemia. Transpl. Int. 24, 1112-1123 (2011
93. Seifert M., Stolk M., Polenz D., & Volk H. D. Detrimental effects of rat mesenchymal stromal cell pre-treatment in a model of acute kidney rejection. Front. Immunol. 3, 202 (2012
94. Koch M., et al. Isogeneic MSC application in a rat model of acute renal allograft rejection modulates immune response but does not prolong allograft survival. Transpl. Immunol. 29, 43-50 (2013
95. Casiraghi F., et al. Localization of mesenchymal stromal cells dictates their immune or proinflammatory effects in kidney transplantation. Am. J. Transplant. 12, 2373-2383 (2012
96. Marquez-Curtis L. A., & Janowska-Wieczorek A. Enhancing the migration ability of mesenchymal stromal cells by targeting the SDF 1/CXCR4 axis. Biomed. Res. Int. 2013, 561098 (2013
97. Cao Z., et al. Protective effects of mesenchymal stem cells with CXCR4 up regulation in a rat renal transplantation model. PLoS ONE 8, e82949 (2013
98. Liu N., Patzak A., & Zhang J. CXCR4 overexpressing bone marrow-derived mesenchymal stem cells improve repair of acute kidney injury. Am. J. Physiol. Renal Physiol. 305, F1064-F1073 (2013
99. Perico N., et al. Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility. Clin. J. Am. Soc. Nephrol. 6, 412-422 (2011
100. Perico N., et al. Mesenchymal stromal cells and kidney transplantation: pretransplant infusion protects from graft dysfunction while fostering immunoregulation. Transpl. Int. 26, 867-878 (2013
101. Tan J., et al. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial. JAMA 307, 1169-1177 (2012
102. Reinders M. E., et al. Autologous bone marrow-derived mesenchymal stromal cells for the treatment of allograft rejection after renal transplantation: results of a phase I study. Stem Cells Transl. Med. 2, 107-111 (2013
103. Mudrabettu C., et al. Safety and efficacy of autologous mesenchymal stromal cells transplantation in patients undergoing living donor kidney transplantation: a pilot study. Nephrology (Carlton) 20, 25-33 (2015
104. Peng Y., et al. Donor-derived mesenchymal stem cells combined with low-dose tacrolimus prevent acute rejection after renal transplantation: a clinical pilot study. Transplantation 95, 161-168 (2013
105. Ruggenenti P., et al. Basiliximab combined with low-dose rabbit anti-human thymocyte globulin: a possible further step toward effective and minimally toxic T cell-targeted therapy in kidney transplantation. Clin. J. Am. Soc. Nephrol. 1, 546-554 (2006
106. Farris A. B., et al. Acute renal endothelial injury during marrow recovery in a cohort of combined kidney and bone marrow allografts. Am. J. Transplant. 11, 1464-1477 (2011
107. Bluestone J. A., et al. The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am. J. Transplant. 8, 2086-2096 (2008
108. US National Library of Science. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02012153 (2015
109. Vincenti F., et al. Costimulation blockade with belatacept in renal transplantation. N. Engl. J. Med. 353, 770-781 (2005
110. Riella L. V., & Chandraker A. Stem cell therapy in kidney transplantation. JAMA 308, 130; author reply 130-131 (2012
111. Griffin M. D., et al. Anti-donor immune responses elicited by allogeneic mesenchymal stem cells: what have we learned so far? Immunol. Cell Biol. 91, 40-51 (2013
112. Badillo A. T., Beggs K. J., Javazon E. H., Tebbets J. C., & Flake A. W. Murine bone marrow stromal progenitor cells elicit an in vivo cellular and humoral alloimmune response. Biol. Blood Marrow Transplant. 13, 412-422 (2007
113. Beggs K. J., et al. Immunologic consequences of multiple, high-dose administration of allogeneic mesenchymal stem cells to baboons. Cell Transplant. 15, 711-721 (2006
114. Isakova I. A., Dufour J., Lanclos C., Bruhn J., & Phinney D. G. Cell-dose-dependent increases in circulating levels of immune effector cells in rhesus macaques following intracranial injection of allogeneic MSCs. Exp. Hematol. 38, 957-967.e1 (2010
115. Zaim M., Karaman S., Cetin G., & Isik S. Donor age and long-term culture affect differentiation and proliferation of human bone marrow mesenchymal stem cells. Ann. Hematol. 91, 1175-1186 (2012
116. Nemeth K. Mesenchymal stem cell therapy for immune-modulation: the donor, the recipient, and the drugs in between. Exp. Dermatol. 23, 625-628 (2014
117. Siegel G., et al. Phenotype, donor age and gender affect function of human bone marrow-derived mesenchymal stromal cells. BMC Med. 11, 146 (2013
118. Remuzzi G., & Bromberg J. S. Mesenchymal stromal cells: what?s in the name? (and for what?). Am. J. Transplant. 13, 1625 (2013
119. von Bahr L., et al. Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy. Biol. Blood Marrow Transplant. 18, 557-564 (2012
120. Forslow U., et al. Treatment with mesenchymal stromal cells is a risk factor for pneumonia-related death after allogeneic hematopoietic stem cell transplantation. Eur. J. Haematol. 89, 220-227 (2012
121. Kawai T., Sachs D. H., Sykes M., & Cosimi A. B. HLA-mismatched renal transplantation without maintenance immunosuppression. N. Engl. J. Med. 368, 1850-1852 (2013